Tukysa (Tucatinib)
- Medicine Name: Tukysa
- Generic Name: Tucatinib
- Dosage Form & Strength: Tablets: 50mg/150mg
- Manufactured By: Seattle Genetics, Inc.
Tukysa is a kinase inhibitor, used along with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2 +Ve breast cancer, including patients with brain metastases, who have received single or multiple prior anti-HER2-based regimens in the metastatic setting.
Recommended Dosage: The recommended dosage is 300 mg taken orally twice daily along with trastuzumab and capecitabine until disease progression or unacceptable toxicity. Patients should swallow tucatinib tablets whole without chewing, crushing, or splitting. Patients should not ingest the tablets in case it is broken, cracked, or not otherwise intact. Tablets should be taken approximately 12 hours apart and persistently each day with or without a meal.
When given along with Tucatinib, the recommended dosage of capecitabine is 1000 mg/m2 orally twice daily taken within 30 minutes after taking a meal. Tucatinib and capecitabine typically can be taken around the same time.
- The tucatinib 50 mg tablets can cause severe diarrhea including hypotension, acute kidney injury, dehydration and death. If diarrhea occurs, administer antidiarrheal therapy.
- Diagnostic tests need to be performed to exclude the other causes of diarrhea. On behalf of the severity of the diarrhea, interrupt dose, then dose reduce or permanently discontinue therapy.
- The tucatinib tablets 50 mg can cause severe hepatotoxicity. Monitor ALT, AST, and bilirubin prior to starting treatment, every 3 weeks during treatment. On behalf of the severity of hepatotoxicity, interrupt dose, then dose reduce or permanently discontinue therapy.
- Females of reproductive potential should use apt contraception during treatment and for at least 7 days after the final dose.
- Findings and its mechanism of action suggest that treatment with tukysa 150 mg tablets can cause fetal harm if administered to a pregnant woman.
- Male patients with female partners of reproductive age or potential should use effective contraception during treatment with Tucatinib and for at least 7 days after the final dose.
- Due to the potential for severe adverse reactions in a breastfed child, women should not breastfeed during treatment with Tucatinib and for at least 7 days after the final dose.
What documents are required to import TUKYSA to India?
TUKYSA (Tucatinib) tablets can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients id proof (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is TUKYSA available in India?
TUKYSA (Tucatinib tablets) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
TUKYSA can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of TUKYSA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for Tucatinib price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements
Indian Pharma Network is able to source the TUKYSA (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Tukysa®?
Tucatinib is Generic Name for the trade name drug Tukysa®.
What is the Manufacturer Name of Tukysa®?
Tukysa® is manufactured by Seattle Genetics, Inc.
Is Tukysa® approved by the FDA?
Yes, Tukysa® is approved by the FDA. Date of approval: On April 17, 2020.
What is Tukysa®?
Tukysa (tucatinib tablets 50mg/150mg) specifically is a tyrosine kinase inhibitor (targeted therapy) that typically targets HER2 found on some types of breast cancer cells.
What is the dosage and form of Tukysa® supplied?
Tukysa® is supplied as Tablets: 50 mg and 150 mg for oral administration.
What are the most common side effects due to Tukysa®?
Most common side effects due to Tukysa® include: rash, diarrhea, palmar-plantar erythrodysesthesia, abdominal pain, hepatotoxicity, vomiting, nausea, fatigue, stomatitis, decreased appetite, headache and anemia.
How much does Tukysa cost in India?
The tukysa cost in India is sensibly reasonable. To procure this HER2-positive breast cancer medicine authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Tukysa®?
Store tablets at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F). Dispense in original container only. Store in the original container for protection from moisture. Replace cap securely every time after opening. Do not discard desiccant.
What are the Highlights of prescribing information for Tukysa®?
Click Here to download full Tukysa prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.